GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)

Market Cap	497.02B
Revenue (ttm)	37.48B
Net Income (ttm)	9.50B
Shares Out	n/a
EPS (ttm)	56.10
PE Ratio	52.30
Forward PE	45.24
Dividend	54.00 (1.69%)
Ex-Dividend Date	May 30, 2025

Volume	282,729
Average Volume	68,469
Open	3,162.90
Previous Close	3,162.60
Day's Range	2,896.20 - 3,184.30
52-Week Range	1,921.00 - 3,515.70
Beta	0.04
RSI	35.97
Earnings Date	Aug 1, 2025

About Ligand Pharmaceuticals

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease;...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1924
• Employees: 3,113
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GLAXO

Financial Performance

In 2024, NSE:GLAXO's revenue was 37.49 billion, an increase of 8.56% compared to the previous year's 34.54 billion. Earnings were 9.28 billion, an increase of 57.23%.